To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

Seltorexant

From Wikipedia, the free encyclopedia

Seltorexant
Clinical data
Other namesMIN-202; JNJ-42847922; JNJ-922
Routes of
administration		By mouth[1]
Drug classOrexin antagonist
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
MetabolismCYP3A4[2]
Elimination half-life2–3 hours[2]
Identifiers
  • [5-(4,6-Dimethylpyrimidin-2-yl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-ylphenyl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H22FN7O
Molar mass407.453 g·mol−1
3D model (JSmol)
  • c4c(C)nc(nc4C)N5CC2CN(CC2C5)C(=O)c1c(cccc1F)-n3nccn3
  • InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+
  • Key:SQOCEMCKYDVLMM-IYBDPMFKSA-N

Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia.[3][2] It is a selective antagonist of the orexin OX2 receptor (2-SORA).[2][4][1] The medication is taken by mouth.[1] As of February 2022, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia.[3] It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication.[3] Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals.[3]

Seltorexant is being explored at doses of 5 to 80 mg.[2] In the early clinical trials conducted so far, seltorexant has been found to improve depression scores on the Hamilton Depression Rating Scale in people with MDD and to improve sleep onset, total sleep time, time awake after sleep onset, and sleep efficiency in people with MDD and/or insomnia.[2][4] Seltorexant is reported to be safe and well-tolerated.[2][4] Side effects of seltorexant observed in clinical trials so far have included somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares.[2]

Seltorexant shows over 100-fold greater binding affinity for the OX2 receptor over the OX1 receptor.[4] This is in contrast to other orexin receptor antagonists like suvorexant, lemborexant, and daridorexant, which are all dual orexin receptor antagonists (DORAs).[4][2] Seltorexant has fast absorption with a time to peak levels of 0.3 to 1.5 hours and has a relatively short duration with an elimination half-life of only 2 to 3 hours.[2][4] No residual effects of the medication were observed 4 hours after daytime administration.[2] The pharmacokinetics of seltorexant are considered to be ideal for sleep induction.[4] Seltorexant is metabolized by the cytochrome P450 enzyme CYP3A4.[2] It is a small-molecule compound and is structurally related to other clinically used orexin receptor antagonists.[5][2]

YouTube Encyclopedic

  • 1/5
    Views:
    34 897
    2 997
    459
    8 267
    1 802
  • Neurobiologic Insights into Major Depressive Disorder: Emerging Therapies with Novel MOAs
  • Insomnia: Co-Management Strategies, Standards of Care, and Emerging Pharmacotherapeutic Options
  • Advancing the Management of Insomnia: Diagnostic and Therapeutic Strategies for Success
  • Buffett's NEWEST Buy: Royalty Pharma RPRX Stock: Cheap? 10x FCF growing 18%! Deep value?
  • 6 Top Penny Stocks To Buy🚀| OCTOBER 2019 |🎃

Transcription

See also

References

  1. ^ a b c Sun Y, Tisdale RK, Kilduff TS (2021). "Hypocretin/Orexin Receptor Pharmacology and Sleep Phases". Front Neurol Neurosci. Frontiers of Neurology and Neuroscience. 45: 22–37. doi:10.1159/000514963. ISBN 978-3-318-06843-6. PMC 8171809. PMID 34052813.
  2. ^ a b c d e f g h i j k l m Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opin Drug Metab Toxicol. 16 (11): 1063–1078. doi:10.1080/17425255.2020.1817380. PMID 32901578. S2CID 221572078.
  3. ^ a b c d "Seltorexant - Janssen Research & Development/Minerva Neurosciences". AdisInsight. 2022-02-28. Retrieved 2022-04-05.
  4. ^ a b c d e f g Jacobson LH, Hoyer D, de Lecea L (January 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. 291 (5): 533–556. doi:10.1111/joim.13406. PMID 35043499. S2CID 248119793.
  5. ^ Christopher JA (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–38. doi:10.4155/ppa.14.46. PMID 25489915.

External links

This page was last edited on 7 January 2024, at 07:20
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy